Celldex Therapeutics, Inc.
CLDX
$32.55
$0.551.70%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 15.00K | 121.00K | -- | 730.00K | 695.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.00K | 121.00K | -- | 730.00K | 695.00K |
| Cost of Revenue | 73.00M | 75.33M | 62.93M | 54.20M | 52.61M |
| Gross Profit | -72.99M | -75.21M | -62.93M | -53.47M | -51.92M |
| SG&A Expenses | 11.45M | 11.94M | 10.69M | 10.39M | 10.82M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 84.45M | 87.27M | 73.62M | 64.59M | 63.43M |
| Operating Income | -84.44M | -87.15M | -73.62M | -63.86M | -62.74M |
| Income Before Tax | -78.69M | -81.32M | -67.04M | -56.60M | -53.80M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -78.69M | -81.32M | -67.04M | -56.60M | -53.80M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -78.69M | -81.32M | -67.04M | -56.60M | -53.80M |
| EBIT | -84.44M | -87.15M | -73.62M | -63.86M | -62.74M |
| EBITDA | -83.58M | -86.34M | -72.79M | -62.98M | -61.87M |
| EPS Basic | -1.18 | -1.22 | -1.01 | -0.85 | -0.81 |
| Normalized Basic EPS | -0.74 | -0.76 | -0.63 | -0.53 | -0.51 |
| EPS Diluted | -1.18 | -1.22 | -1.01 | -0.85 | -0.81 |
| Normalized Diluted EPS | -0.74 | -0.76 | -0.63 | -0.53 | -0.51 |
| Average Basic Shares Outstanding | 66.57M | 66.49M | 66.42M | 66.39M | 66.38M |
| Average Diluted Shares Outstanding | 66.57M | 66.49M | 66.42M | 66.39M | 66.38M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |